On January 20, 2026, Jonathan Zalevsky, serving as Chief Research and Development Officer at Nektar Therapeutics (NASDAQ: NKTR), officially sold 3,867 shares of the company's common stock. This transaction was documented in a Form 4 filing submitted to the U.S. Securities and Exchange Commission. The sale price varied slightly per share, ranging from $35.17 up to $36.23, resulting in a weighted average sale price of $35.67 per share. Overall, the disposition totaled $137,935 in value.
Post-sale, Zalevsky retains direct ownership of 21,354 shares in Nektar Therapeutics, maintaining a significant equity position within the organization.
In recent developments, Nektar Therapeutics has been under analyst scrutiny following the results of its Phase 2b REZOLVE-AA clinical study targeting alopecia areata. While the trial did not meet its primary endpoint—statistical significance was narrowly missed—the results sparked interest due to meaningful findings revealed through post-hoc analyses excluding certain patient subsets. In response, H.C. Wainwright raised its price target for Nektar to $135, corroborating their Buy stance. Similarly, Jefferies reaffirmed its Buy rating with a target price maintained at $121, emphasizing the confirmed safety and efficacy of the treatment under study.
Oppenheimer also uplifted its price target to $115, underscoring the potential importance of efficacy signals emerging when excluding specific patient cohorts in the analysis. Despite these analyst endorsements, the primary endpoint remained unachieved, with the 24 µg/kg dosage arm demonstrating a 28.2% reduction in the Severity of Alopecia Tool (SALT) score compared to an 11.2% improvement seen in the placebo group.
Meanwhile, Terra Innovatum Global disclosed updates regarding executive remuneration, revealing new compensation agreements and bonuses for key leadership figures. The company's Remuneration Committee ratified directorship agreements for CEO Alessandro Petruzzi, CSO Massimo Morichi, and COO Cesare Frepoli, setting fixed yearly compensations for fiscal years 2025 and 2026.